For UK and Republic of Ireland healthcare professionals only.

This website focuses on chronic sialorrhea in adults. Further information
on sialorrhea in children with neurological and neurodevelopmental
disorders aged 2-17 and >12kg is available on the paediatric webpage.

REPORT AN ADVERSE EVENT
SIALORRHEA IN PAEDIATRICS

SIALORRHEA CAN NEGATIVELY
IMPACT PATIENTS’ QUALITY
OF LIFE AND CONTRIBUTE
TO SOCIAL ISOLATION.1,2

XEOMIN® is indicated in adults for the symptomatic treatment of:

XEOMIN® (botulinum neurotoxin type A)
  • blepharospasm and hemifacial spasm,
  • cervical dystonia of a predominantly rotational form
    (spasmodic torticollis),
  • spasticity of the upper limb
  • chronic sialorrhea due to neurological disorders.
  • focal spasticity of the lower limb affecting the
    ankle joint - UK ONLY

XEOMIN® is the first and only pharmacological product approved for the treatment of chronic sialorrhea due to neurological disorders in adults.3

XEOMIN® (botulinum neurotoxin type A) is recommended by NICE, within its marketing authorisation, as an option for treating chronic sialorrhea caused by neurological conditions in adults. It is recommended only if the company provides it according to the commercial arrangement.4

XEOMIN® showed a significant reduction in salivary flow rate vs placebo5

In SIAXI, a prospective, placebo-controlled, randomised, double-blind, parallel-group phase III study (n=184), XEOMIN® demonstrated:

XEOMIN® demonstrated a significant reduction in salivary flow by up to 33% versus up to 11% with placebo5

The coprimary endpoints were the change in unstimulated salivary flow rate (uSFR) from study baseline to week 4, and the patients’ Global Impression of Change Scale (GICS) score at week 4.

PERCENTAGE CHANGE FROM BASELINE IN uSFR
Graph showing Change From Baseline in uSFR

Adapted from Jost WH et al. 2019.

  • Study includes adult patients with Parkinson's, Atypical parkinsonism, Stroke or Traumatic Brain Injury (TBI)5
  • Sustained reductions in salivary flow were observed with repeat treatments over 64 weeks6
  • Significant improvements in patients’ perception of functioning vs. placebo at week 4 (p=0.002)5

XEOMIN® has an established tolerability and safety profile5,7

Most common treatment-emergent adverse events (TEAEs)

TEAEs were defined as adverse events (AEs) with onset or worsening at or after the 1st injection of XEOMIN® or placebo up to and before 1st injection of extension period (EP) or in case of discontinuation before EP up to and including 16 weeks after 1st injection or date of last study visit, whichever was later. Placebo (n=36) XEOMIN® 75 U (n=74) XEOMIN® 100 U (n=74)
Percentage of patients
Fall 0 8.1 (6) 2.7 (2)
Dry mouth 0 5.4 (4) 4.1 (3)
Hypertension 2.8 (1) 2.7 (2) 4.1 (3)
Contusion 0 5.4 (4) 0
Tooth extraction 0 0 5.4 (4)
Diarrhoea 2.8 (1) 1.4 (1) 4.1 (3)
Dysphagia 0 4.1 (3) 0
Urinary tract infection 0 4.1 (3) 0

XEOMIN® is injected directly into the salivary glands providing targeted treatment of sialorrhea4

The following videos give guidance for injecting
with the use of ultrasound.

XEOMIN® videos labelled diagram

Injection Training:
Treatment of the parotid gland

Injection Training:
Treatment of the submandibular gland

Recommended dosage
by injection location3

The timing for repeat treatment should be determined based on the actual clinical need of the individual patient, and no sooner than every 16 weeks.

GLAND(S) UNITS PER SIDE TOTAL
Parotid gland(s) 30 Units 60 Units
Submandibular gland(s) 20 Units 40 Units
Total 50 Units 100 Units

Case studies

Making a difference in sialorrhea

The following resources are available for download:

Contact us

contact form

By emailing and registering my data with Merz, I acknowledge that Merz Therapeutics may process my personal data in accordance with their privacy policy. I also acknowledge that Merz Therapeutics may use my personal data to contact me via email for marketing purposes.

What’s NEXT?

What is your goal with your patients?
Let’s take BoNT therapy to the next level, together.

NEXT logo
back to top arrow up Back to Top

THIS WEBSITE IS FOR
HEALTHCARE PROFESSIONALS ONLY

Are you a UK healthcare professional?

Privacy Policy

Date of preparation: February 2024 M-XEO-UKI-1336

THIS WEBSITE IS FOR XEOMIN
(BOTULINUM NEUROTOXIN TYPE A)
IMPROVING SALIVA CONTROL

Would you like to explore saliva control in adults or paediatrics?

Privacy Policy

Date of preparation: February 2024 M-XEO-UKI-1336